(BPT) – Article is sponsored and developed by BioLineRx USA, Inc. Receiving a cancer diagnosis is overwhelming. There is a lot to learn while navigating numerous emotions. It’s always important to ...
Dr. Michael Linenberger of Fred Hutchinson Cancer Research Center has been awarded one of the highest honors in the field of apheresis, the medical subspecialty that uses automated methods to separate ...
The fifth annual Apheresis Awareness Day is recognized on Tuesday, September 17, 2024, as designated by the American Society for Apheresis (ASFA). The purpose is to raise awareness of apheresis ...
“The Transfusion Medicine Service in the Department of Pathology performs therapeutic apheresis on patients who have an illness associated with an abnormal cellular or plasma-based blood component,” ...
Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required by gene therapies for sickle cell disease within a single apheresis cycle ...
After 10 years of stagnation, a new FDA approval could help more cancer patients become eligible for stem cell transplants. Monday, Israeli drugmaker BioLineRx said the FDA approved motixafortide—also ...
Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback